Abstract: OBJECTIVE To analyze the risk factors for invasive fungal infection（IFI） in the children with nephrotic syndrome（NS） and observe the levels of serum procalcitonin（PCT） and C-reactive protein（CRP）. METHODS A total of children with NS who were treated in the Xinxiang Central Hospital from Sep 2017 to Sep 2019 were retrospectively analyzed and were divided into the infection group with 46 cases and the non-infection group with 201 cases according to the status of IFI infection during treatment period. The samples were collected from the infection sites of the children so as to carry out the fungal culture. The age, type of kidney disease, length of hospital stay, and levels of serum albumin（ALB）, immunoglobulin A（IgA） and IgG were observed. The levels of serum white blood cell（WBC）, interleukin-6（IL-6）, CRP and PCT were detected before the treatment and after the treatment for 2 weeks. The value of serum WBC, IL-6, PCT and CRP in prediction of IFI was analyzed by means of receiver operating characteristic（ROC） curve, and logistic model analysis was performed for risk factors for IFI. RESULTS Among the 247 children with NS, the incidence rate of IFI was 18.62%. Among the isolated fungi, 91.30% were Candida, and 8.70% were Aspergillus. The less than 3 years of age（OR=1.881,P=0.027）, ALB less than 20 g/L（OR=1.815,P=0.043） and length of hospital stay no less than 30 days（OR=1.937, P=0.016） were the independent risk factors for IFI. The areas under curve（AUCs） of serum WBC, IL-6, PCT and CRP were respectively 0.650, 0.708, 0.762 and 0.733 in prediction of IFI（P＜0.05）, the AUC of joint detection of the above indexes was 0.909 in prediction of IFI（P＜0.05）. The levels of serum WBC, IL-6, PCT and CRP of the NS children complicated with IFI were significantly lower after the treatment than before the treatment（P＜0.05）. CONCLUSION The less than 3 years of age, serum ALB less than 20 g/L and length of hospital stay no less than 30 days are the independent risk factors for IFI in the children with NS. The clinicians can assess the progression of IFI and guide the clinical treatment based on the levels of serum PCT and CRP.